Recent Updates
Recently added Catalysts

JZP-110

Phase 3

Narcolepsy | Small molecule | Other |Jazz Pharmaceuticals plc|Last Updated: Jan 13, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials3
Total Enrollment908
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02348593"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"PHASE3 COMPLETED 239May 1, 2015Feb 1, 2017Jul 23, 201960 United States, Canada +4
NCT02348632"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"PHASE3 COMPLETED 645May 1, 2015Dec 1, 2017Jun 25, 201980 United States, Canada +4
NCT02806908Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in NarcolepsyPHASE2 COMPLETED 24Jun 1, 2016May 19, 2019Jan 13, 20211 Netherlands
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12
Baseline to Week 12

Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake; a positive change from baseline represents improvement in the sleep latency time. Mean sleep latency defined as the average of the first 4 MWT trials, if 3 or 4 of them are non-missing.

Change in ESS Score From Baseline to Week 12
Baseline to Week 12

Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.

Change in Epworth Sleepiness Scale (ESS) Score
Start of randomized withdrawal phase to end of randomized withdrawal (2 weeks)

Change in Epworth Sleepiness Scale (ESS) score during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. This analysis included treatment group and randomization stratification factor (narcolepsy vs. OSA) as fixed effects. The ESS score at the beginning of the randomized withdrawal period was used as the covariate. The response variable was the change in ESS score from the beginning to the end of 2- week randomized withdrawal period.

Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax)
2 hours post-dose

Subjects were instructed to drive with steady lateral position between the delineated boundaries of the slower (right) traffic lane, while maintaining a constant speed of 95 kilometers (km) per hour (hr). Deviation was measured by the vehicle's speed and lateral distance to the left lane line and was continuously recorded. Individual improvement was defined as a decrease in SDLP below the negative value of threshold; individual impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Secondary Endpoints
Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12
Baseline to Week 12
Change in Sleep Latency Time on MWT Trial 1 at Week 12
Change from baseline for sleep latency in MWT during trial 1 at week 12
Change in Sleep Latency Time on MWT Trial 2 at Week 12
Change from baseline for sleep latency in MWT during trial 2 at week 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
75 mg of JZP-110ACTIVE_COMPARATOROnce Daily Dosing
150 mg JZP-110ACTIVE_COMPARATOROnce Daily Dosing
300 mg of JZP-110ACTIVE_COMPARATOROnce Daily Dosing
PlaceboPLACEBO_COMPARATOROnce Daily Dosing
75 mg - 300 mg of JZP-110OTHEROnce Daily Dosing
JZP-110ACTIVE_COMPARATOR150 mg/day for first 3 days and 300 mg/day for next 4 days
Interventions
NameTypeDescription
JZP-110DRUG -
Placebo oral tabletDRUG -
PlaceboDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites60

Major Inclusion Criteria: 1. Males and females between 18 and 75 years of age, inclusive 2. Diagnosis of narcolepsy according to ICSD-3 or DSM-5 criteria 3. Body mass index from 18 to \<45 kg/m2 4. Consent to use a medically acceptable method of contraception 5. Willing and able to provide written ...

Countries:United StatesCanadaFinlandFranceGermanyNetherlands
Unlock Eligibility Criteria